Thomas H. Kean
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsThomas H. Kean sold $1,001 - $15,000 in $JNJ on 2026-03-26 — 1 day BEFORE HR8143, which mandates Medicare Part D plans to include generic and biosimilar drugs, potentially reducing brand-name drug sales.
Thomas H. Kean sold $15,001 - $50,000 in $SPGI on 2026-03-26 — 9 days AFTER SJRES129, which re-establishes state authority over credit reporting, potentially increasing compliance costs for credit reporting agencies.
Thomas H. Kean sold $15,001 - $50,000 in $PEP on 2026-03-26 — 10 days AFTER HR7945, a bill proposing to ban the sale of nitrous oxide consumer products.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AMCR | Amcor plc Ordinary Shares (AMCR) | $1K-$15K | $39.75 | $38.38 | -3.4% | Mar 31, 2026 |
| BUY | $LIN | Linde plc - Ordinary Shares (LIN) | $1K-$15K | $495.49 | $517.58 | +4.5% | Mar 26, 2026 |
| PARTIAL SELL | $CB | Chubb Limited Common Stock (CB) | $15K-$50K | $324.31 | $327.89 | +1.1% | Mar 26, 2026 |
| PARTIAL SELL | $PEP | Pepsico, Inc. (PEP) | $15K-$50K | $150.83 | $150.57 | -0.2% | Mar 26, 2026 |
| PARTIAL SELL | $SPGI | S&P Global Inc. Common Stock (SPGI) | $15K-$50K | $412.45 | $417.60 | +1.2% | Mar 26, 2026 |
| PARTIAL SELL | $FCNCA | First Citizens BancShares, Inc. - Class A Common Stock (FCNCA) | $1K-$15K | $1,896.78 | $1,991.55 | +5.0% | Mar 26, 2026 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock (JNJ) | $1K-$15K | $239.26 | $234.34 | -2.1% | Mar 26, 2026 |
| PARTIAL SELL | $WAT | Waters Corporation Common Stock (WAT) | $1K-$15K | $299.63 | $342.37 | +14.3% | Mar 10, 2026 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Protecting Americans from Unsafe Drugs Act of 2026
The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) would expand FDA mandatory recall authority from controlled substances to all drugs, increasing structural operational risk and compliance costs for major pharmaceutical manufacturers. The bill is at an early legislative stage with a single Democratic sponsor, giving it low near-term passage probability. Market data shows the sector is already under pressure in April 2026 with JNJ, PFE, MRK, and AZN all down significantly over 30 days, but this bill is not yet being priced in as a material risk.
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
This $65.0 million contract for pharmaceuticals and related supplies, awarded to DLA Troop Support by the NIH, is likely to benefit major pharmaceutical companies as prime or sub-contractors, driven by ongoing federal healthcare needs. The award aligns with legislative support for healthcare services, suggesting a stable demand environment.
To ban the sale of nitrous oxide consumer products, and for other purposes.
HR7945, the Nitrous Oxide Safety Act of 2026, is an early-stage bill referred to the House Energy and Commerce Committee. It would ban consumer products containing nitrous oxide but carves out broad exemptions for medical/dental use, commercial food production, and food products using N2O as a propellant — meaning no impact on major food/beverage companies. The bill has only one sponsor (a junior member) and one cosponsor, with no further legislative action since introduction. Market data shows no bill-related price movements.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
HR8143 mandates Medicare Part D formularies give preferred placement to generic drugs and biosimilars with lower wholesale acquisition costs than brand-name reference products, effective January 1, 2027. This directly benefits pure-play generics manufacturers $VTRS and $TEVA by guaranteeing formulary access and restricting PBM utilization management. The bill is early stage (referred to committee) but has bipartisan sponsorship and clear structural impact on the Part D market.
Strengthening the Vaccines for Children Program Act of 2026
HR8425 is an early-stage authorization bill that expands VFC eligibility and mandates minimum Medicaid vaccine administration reimbursement rates, but it contains no funding appropriations. Market data shows no price reaction from PFE or MRNA following introduction. The bill is unlikely to generate material revenue changes for vaccine manufacturers without separate appropriations bills.
Fair Compensation for Truck Crash Victims Act
HR8218 proposes a 567% increase in minimum liability insurance for trucking companies, structurally raising operating costs by $6k–$16k per truck annually. The bill is in early committee stage with only 5 cosponsors, suggesting low near-term passage probability. If enacted, asset-heavy carriers like KNX and JBHT face direct margin compression, while commercial auto insurers (HIG, CB) would benefit from larger premiums on the same fleet base. Market data shows trucking stocks recently rallied ~10–24% over 30 days, but this bill's introduction has not yet been priced in, creating downside risk for long holders.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877 (Shane DiGiovanna Act) mandates a 2-year nationwide Medicaid demonstration program covering wound care and OTC drugs for epidermolysis bullosa. The bill is in early legislative stages (referred to committee, 5 cosponsors) with no explicit funding authorized. Market impact is minimal — the affected patient population is small (~3,000-5,000 individuals), and near-term passage is uncertain.
To amend the Public Health Service Act with respect to the Living Organ Donation Reimbursement Program.
HR7868, the 'Expanding Support for Living Donors Act of 2026,' is an early-stage bill authorizing up to $10,000 per donor for qualifying expenses in FY2027. Actual appropriations are required. The market reaction in diagnostic ($LH, $DGX) and device ($MDT, $SYK) stocks is currently driven by broader market trends — all four stocks are down 2-9% over the past 30 days — not by this bill's introduction. The legislative impact on revenue is negligible at this stage.
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "The Fair Credit Reporting Act's Limited Preemption of State Laws".
S.J. Res. 129 is a CRA disapproval resolution nullifying the CFPB's withdrawal of FCRA preemption, reimposing a costly 50-state regulatory patchwork for credit reporting. This directly raises operating expenses for Equifax ($EFX) and FICO ($FICO) as compliance costs increase, and pressures national lenders Capital One ($COF) and American Express ($AXP) to adapt uniform credit systems to state-specific regulations. The bill is on the Senate calendar with fast-track CRA rules, making floor action imminent.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
Other Filings by Thomas H. Kean
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.